PTP4A3 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL885403	0.83	12/20
SCHEMBL885404	0.83	12/20
SCHEMBL2067675	0.77	12/20
SCHEMBL2067676	0.77	12/20
SCHEMBL2065377	0.70	12/20
SCHEMBL2065379	0.70	12/20
SCHEMBL2065862	0.64	12/20
SCHEMBL2066221	0.62	12/20
SCHEMBL2066172	1.00	11/20
SCHEMBL2066174	1.00	11/20
SCHEMBL2065850	0.86	11/20
SCHEMBL2065852	0.86	11/20
SCHEMBL885422	0.83	11/20
SCHEMBL2065839	0.83	11/20
SCHEMBL2066162	0.81	11/20
SCHEMBL2066164	0.81	11/20
SCHEMBL2065201	0.81	11/20
SCHEMBL2065204	0.81	11/20
SCHEMBL2067124	0.78	11/20
SCHEMBL2066185	0.76	11/20

Clinical trials — most relevant to PTP4A3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Effect of Sitagliptin, Pioglitazone and Dapagliflozine on Myocardial Infarction in Diabetic Rats	PHASE4	COMPLETED
Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance	PHASE4	UNKNOWN
Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion	PHASE2	ACTIVE_NOT_RECRUITING
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma	PHASE2	RECRUITING
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian Cancer	PHASE2	RECRUITING
Imatinib in Dermatofibrosarcoma Protuberans (DFSP)	PHASE1/PHASE2	COMPLETED
A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma	PHASE2	UNKNOWN
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors	PHASE1	WITHDRAWN
Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas	PHASE1	COMPLETED
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease	nan	UNKNOWN
Monitoring of Breathing Effort Through Pressure Time Product Measurement Using Airway Occlusion Pressure	nan	UNKNOWN
Identification of the Genetic Variants Responsible for Primary Biliary Cirrhosis (PBC)	nan	UNKNOWN
Study of Constitutional Platelet Disease	nan	UNKNOWN
Cardiovascular Effects of Empagliflozine	nan	UNKNOWN
New Biomarkers for Diagnosis and Follow-up of Patients With LRBA or CTLA4 Deficiencies	nan	UNKNOWN
Cytotoxic T Lymphocyte-Associated Antigen-4 (CTLA-4) Gene Single-nucleotide Polymorphism in Primary Immune Thrombocytopenic Purpura in Children	nan	NOT_YET_RECRUITING
Immune Signature of Palmoplantar Pustulosis	nan	COMPLETED
Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors	nan	UNKNOWN
Markers and Mechanisms of Macrovascular Disease in IDDM	nan	COMPLETED
NGS in Gallbladder Cancer and Response to Treatment	nan	RECRUITING
The Effect of Sitagliptin on Hypertension, Arterial Stiffness, Oxidative Stress and Inflammation	nan	UNKNOWN
IgA Nephropathy Biomarkers Evaluation Study (INTEREST)	nan	RECRUITING
Investigation of Copy Number Variations and Genetic Variants in POI	nan	RECRUITING
Pathophysiology of Paget's Disease of Bone	nan	COMPLETED
Nephron Sparing Renal Surgery and Total Nephrectomy	nan	COMPLETED
Methylation of DNA in Children and Adolescents With Type 1 Diabetes Mellitus (METHYLDIAB)	nan	COMPLETED
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients.	nan	COMPLETED
Multicenter Study of Patients With SHANK3 Mutations: Identification of Genes Modificators in Phelan-McDermid Syndrome (EUQ13)	nan	NOT_YET_RECRUITING
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a PTP4A3 binder may also engage these)

Protein	Name	Similarity
A2VDT1	—	1.000	A2VDT1 →
PTP4A1	Protein tyrosine phosphatase type IVA 1	1.000	landscape →
Q9D658	—	1.000	Q9D658 →
Q63739	—	1.000	Q63739 →
Q9TSM6	—	1.000	Q9TSM6 →
Q78EG7	—	1.000	Q78EG7 →
Q5R7J8	—	1.000	Q5R7J8 →
O61722	—	0.999	O61722 →
PTP4A2	Protein tyrosine phosphatase type IVA 2	0.997	landscape →
Q6P9X4	—	0.997	Q6P9X4 →
O70274	—	0.997	O70274 →
Q4CUJ8	—	0.993	Q4CUJ8 →
Q54DU9	—	0.992	Q54DU9 →
Q86IL4	—	0.990	Q86IL4 →
Q4QEZ7	—	0.988	Q4QEZ7 →
Q9ZR37	—	0.980	Q9ZR37 →
P0DOQ6	—	0.980	P0DOQ6 →
A0A7H0DN78	—	0.979	A0A7H0DN78 →
Q4R7L5	—	0.979	Q4R7L5 →
Q6GQJ8	—	0.979	Q6GQJ8 →
P20495	—	0.979	P20495 →
CAMK2D	Calcium/calmodulin-dependent protein kinase type II subunit delta	0.979	landscape →
Q8LL05	—	0.979	Q8LL05 →
P07239	—	0.979	P07239 →
P25044	—	0.978	P25044 →
P11730	—	0.978	P11730 →
P80994	—	0.978	P80994 →
F4IDQ6	—	0.978	F4IDQ6 →
Q5XI69	—	0.978	Q5XI69 →
Q85297	—	0.978	Q85297 →